Alladapt Immunotherapeutics: Funding, Investors & Team (Sep 2026)
Alladapt Immunotherapeutics is a secretly held biopharmaceutical organization creating solution therapeutics focusing on food sensitivity. The Company's lead program, ADP101, is being progressed as a wide range oral immunotherapy treatment to moderate food sensitivity set off by single or different proteins from an extensive arrangement of normal allergens.
Alladapt Immunotherapeutics has raised $119M across 1 funding round on record, the most recent an undisclosed round of $119M announced in Jun 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Alladapt Immunotherapeutics Company Profile and Key Stats
Latest funding round on record: Jun 2022.
Alladapt Immunotherapeutics Funding Rounds
Alladapt Immunotherapeutics Founders and Leadership Team
Contact details for the Alladapt Immunotherapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Alladapt Immunotherapeutics Funding Compared to Other Biotechnology Startups
Alladapt Immunotherapeutics' latest round of $119M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Alladapt Immunotherapeutics in Biotechnology and Menlo Park
Companies Similar to Alladapt Immunotherapeutics
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Alladapt Immunotherapeutics Funding FAQs
What does Alladapt Immunotherapeutics do?
Alladapt Immunotherapeutics is a secretly held biopharmaceutical organization creating solution therapeutics focusing on food sensitivity. The Company's lead program, ADP101, is being progressed as a wide range oral immunotherapy treatment to moderate food sensitivity set off by single or different proteins from an extensive arrangement of normal allergens.
How much funding has Alladapt Immunotherapeutics raised?
Alladapt Immunotherapeutics has raised $119M across 1 round on record. The most recent is an undisclosed round of $119M announced in Jun 2022.
When did Alladapt Immunotherapeutics last raise funding?
Alladapt Immunotherapeutics' most recent funding round on record is an undisclosed round of $119M, announced in Jun 2022.
Who is the CEO of Alladapt Immunotherapeutics?
Ashley Dombkowski is listed as CEO at Alladapt Immunotherapeutics.
Where is Alladapt Immunotherapeutics headquartered?
Alladapt Immunotherapeutics is based in Menlo Park, California, United States.
How many employees does Alladapt Immunotherapeutics have?
Alladapt Immunotherapeutics is in the 11-50 employee band.
How does Alladapt Immunotherapeutics' funding compare to other Biotechnology startups?
Alladapt Immunotherapeutics' latest round of $119M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Alladapt Immunotherapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Alladapt Immunotherapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.